# TRAF3IP3

## Overview
TRAF3IP3 is a gene that encodes the TRAF3 interacting protein 3, which is an adaptor protein involved in the regulation of immune responses, particularly in antiviral signaling pathways. The protein plays a crucial role in modulating the type I interferon (IFN-I) signaling pathway by promoting the degradation of TBK1, a key kinase in antiviral responses, thereby maintaining immune homeostasis and preventing excessive inflammation (Deng2020TRAF3IP3). TRAF3IP3 specifically interacts with TRAF3 and TBK1, influencing the TBK1-IRF3 axis and attenuating IFN-I responses (Deng2020TRAF3IP3). Beyond its role in antiviral defense, TRAF3IP3 is also involved in the maturation and function of immune cells, such as NKT2 cells, through the MEK/ERK signaling pathway (Zhang2019TRAF3IP3). The gene's clinical significance is underscored by its association with various diseases, including childhood B-cell acute lymphoblastic leukemia and autoimmune conditions like Graves' disease (Pommert2021Novel; Hu2021Screening).

## Function
TRAF3IP3, also known as TRAF3 interacting protein 3, plays a significant role in regulating immune responses in human cells. It functions as a negative regulator of cytosolic RNA-induced antiviral signaling by promoting the K48-linked polyubiquitination and degradation of TBK1, a key kinase in the antiviral response. This process is crucial for modulating the type I interferon (IFN-I) signaling pathway, thereby maintaining immune homeostasis and preventing excessive inflammation (Deng2020TRAF3IP3).

TRAF3IP3 interacts with TRAF3 and TBK1, but not with other components like RIG-I, MAVS, or IRF3, indicating its specific role in the signaling cascade leading to IFN-I production. It competes with MAVS for binding to TRAF3, thereby attenuating the TBK1-IRF3 axis and reducing IFN-I responses (Deng2020TRAF3IP3).

In addition to its role in antiviral signaling, TRAF3IP3 is involved in the maturation and function of immune cells, such as NKT2 cells, through the MEK/ERK signaling pathway. It promotes the activation of MEK and ERK, which are essential for the functional maturation of these cells (Zhang2019TRAF3IP3).

## Clinical Significance
Mutations and alterations in the TRAF3IP3 gene have been implicated in various diseases and conditions. In the context of childhood B-cell acute lymphoblastic leukemia (B-ALL), a novel germline chromosomal structural variant in TRAF3IP3 has been identified, suggesting a predisposition to leukemia by promoting the expansion of immature B-cell precursors susceptible to secondary somatic mutations (Pommert2021Novel). 

TRAF3IP3 also plays a role in immune responses, particularly in antiviral signaling. It negatively regulates cytosolic RNA-induced antiviral signaling by promoting the degradation of TBK1, a key kinase in the antiviral response. This regulation affects the activation of IRF3, impacting the production of type I interferons (Deng2020TRAF3IP3). Alterations in TRAF3IP3 expression have been associated with increased susceptibility to viral infections, such as Enterovirus 71 (EV71), where TRAF3IP3 exhibits antiviral activity by inhibiting viral replication (Li2022TRAF3IP3).

In autoimmune conditions, a single nucleotide variant in TRAF3IP3 has been linked to familial Graves' disease, suggesting its role as a candidate susceptibility gene for this thyroid-related autoimmune disorder (Hu2021Screening). These findings highlight the clinical significance of TRAF3IP3 in various immune-related and oncological conditions.

## Interactions
TRAF3IP3 (TRAF3 interacting protein 3) is involved in several key interactions within the antiviral immune response. It acts as an adaptor protein, facilitating the recruitment of TRAF3 to MAVS (mitochondrial antiviral-signaling protein), which is crucial for the activation of the TBK1-IRF3 signaling pathway. This interaction is specific to MAVS-Region III, which lacks a TRAF-binding motif, indicating the presence of unknown molecules that mediate this recruitment (Zhu2019TRAF). 

TRAF3IP3 also interacts with TBK1, promoting its K48-linked polyubiquitination and degradation, a process dependent on the E3 ligase DTX4. This interaction negatively regulates the RIG-I-MAVS-TBK1 signaling pathway, thereby modulating the immune response to viral infections (Deng2020TRAF3IP3). 

In the context of viral infections, TRAF3IP3 interacts with the 3C protease of Enterovirus 71 (EV71), where it is cleaved at the 87Q-88G site. This cleavage is part of the virus-host interaction, affecting the antiviral activity of TRAF3IP3 (Li2022TRAF3IP3). These interactions highlight TRAF3IP3's role in regulating immune signaling pathways and its involvement in the host's defense mechanisms against viral infections.


## References


[1. (Zhu2019TRAF) Wenting Zhu, Jiaxin Li, Rui Zhang, Yixiang Cai, Changwan Wang, Shishi Qi, She Chen, Xiaozhen Liang, Nan Qi, and Fajian Hou. <scp>traf</scp> 3 <scp>ip</scp> 3 mediates the recruitment of <scp>traf</scp> 3 to <scp>mavs</scp> for antiviral innate immunity. The EMBO Journal, August 2019. URL: http://dx.doi.org/10.15252/embj.2019102075, doi:10.15252/embj.2019102075. This article has 36 citations.](https://doi.org/10.15252/embj.2019102075)

[2. (Zhang2019TRAF3IP3) Xinwei Zhang, Ke Wang, Weijia Zhao, Li Cao, Shusong Zhang, Rong Jin, Xiuyuan Sun, Jie Hao, Xiaojun Huang, Mingzhao Zhu, Hounan Wu, Hongshan Zhao, and Qing Ge. Traf3ip3 at the trans-golgi network regulates nkt2 maturation via the mek/erk signaling pathway. Cellular &amp; Molecular Immunology, 17(4):395–406, May 2019. URL: http://dx.doi.org/10.1038/s41423-019-0234-0, doi:10.1038/s41423-019-0234-0. This article has 7 citations.](https://doi.org/10.1038/s41423-019-0234-0)

[3. (Li2022TRAF3IP3) Hui Li, Yunfang Yao, Yu Chen, Shuangling Zhang, Zhi Deng, Wentao Qiao, and Juan Tan. Traf3ip3 is cleaved by ev71 3c protease and exhibits antiviral activity. Frontiers in Microbiology, June 2022. URL: http://dx.doi.org/10.3389/fmicb.2022.914971, doi:10.3389/fmicb.2022.914971. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmicb.2022.914971)

[4. (Pommert2021Novel) Lauren Pommert, Robert Burns, Quinlan Furumo, Kirthi Pulakanti, Jon Brandt, Michael J. Burke, and Sridhar Rao. Novel germline traf3ip3 mutation in a dyad with familial acute b lymphoblastic leukemia. Cancer Reports, January 2021. URL: http://dx.doi.org/10.1002/cnr2.1335, doi:10.1002/cnr2.1335. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cnr2.1335)

[5. (Hu2021Screening) Zhuoqing Hu, Wei Li, Miaosheng Li, Hao Wei, Zhihui Hu, Yanting Chen, Ai Luo, and Wangen Li. Screening of graves’ disease susceptibility genes by whole exome sequencing in a three-generation family. BMC Medical Genomics, February 2021. URL: http://dx.doi.org/10.1186/s12920-020-00865-z, doi:10.1186/s12920-020-00865-z. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12920-020-00865-z)

[6. (Deng2020TRAF3IP3) Meng Deng, Jason W. Tam, Lufei Wang, Kaixin Liang, Sirui Li, Lu Zhang, Haitao Guo, Xiaobo Luo, Yang Zhang, Alex Petrucelli, Beckley K. Davis, Brian J. Conti, W. June Brickey, Ching-Chang Ko, Yu L. Lei, Shaocong Sun, and Jenny P. -Y. Ting. Traf3ip3 negatively regulates cytosolic rna induced anti-viral signaling by promoting tbk1 k48 ubiquitination. Nature Communications, May 2020. URL: http://dx.doi.org/10.1038/s41467-020-16014-0, doi:10.1038/s41467-020-16014-0. This article has 42 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-16014-0)